COVID-19 Therapeutic Development With Synthetic Antibody Technology

Sachdev Sidhu
Toronto Recombinant Antibody Centre
The Donnelly Centre
University of Toronto



Natural Antibodies



Toronto Recombinant Antibody Centre

A High-throughput synthetic antibody platform

Highly Validated Technology

- a fully human protein
- Highly stable
- Long half-life (weeks)
- Highly potent
- Highly specific
- Low immunogenicity
- Identical to natural neutralizing antibodies
- **A validated human therapeutic**
- **(> 50 approved drugs)**







-Single, highly validated human framework (Hereceptin, Avastin, Xolair, etc.)

-High stability and yield, low immunogenicity

-Minimal targeted synthetic CDR diversity

→Diverse functions with fixed biophysics

→Modular design

The Therapeutic Antibody War Chest

Functional genomics platform



+

Large-scale, industry-quality antibody generation



+

Preclinical biology in relevant models



>14,000 Antibodies
>1,300 Antigens



Donnelly Centre for Cellular + Biomolecular Research UNIVERSITY OF TORONTO | UNIVERSITY OF TORONTO

COVID-19 and the Immune System



COVID-19 virus SARS-2: Spike infection protein



- **SARS-2 is nearly identical to SARS-1 (80%)**
- **Spike protein mediates host recognition and entry (infection)**
- **RBD recognizes host receptor ACE2**
- **Most natural SARS-1 neutralizing antibodies bind to the RBD and compete for binding with ACE2**
- **Develop synthetic antibodies that bind SARS-2 RBD and compete for binding with ACE2**
- **THESE ARE PRIME CANDIDATES FOR BIOLOGIC THERAPEUTICS FOR COVID19**

Validated Antibody Platform for Anti-Virals

Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge



Sidhu and colleagues:*dx.doi.org/10.1021/cb5006454 | ACS Chem. Biol., 2014*

-Similar to SARS-CoV-1/2, Ebola has an acute life cycle
-Developed humanized Abs to key epitope on Ebola virus
-Treatment with single Ab protected virtually all mice from Ebola challenge
-Surviving mice proved resistant to subsequent Ebola challenge
-Ab cleared initial Ebola challenge *and* enabled host immune system to develop natural resistance

Synthetic Neutralizing Antibodies – Proven Stability and Efficacy
-Rapid Development and Scalable Cost-effective Production

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan[a,b,1], Bende Liu[c,1], Cesheng Li[d,1], Huajun Zhang[e,1], Ting Yu[f,1], Jieming Qu[g,h,i,1], Min Zhou[g,h,i,1], Li Chen[j,1], Shengli Meng[b], Yong Hu[d], Cheng Peng[e], Mingchao Yuan[k], Jinyan Huang[l], Zejun Wang[b], Jianhong Yu[d], Xiaoxiao Gao[e], Dan Wang[k], Xiaoqi Yu[m], Li Li[b], Jiayou Zhang[b], Xiao Wu[d], Bei Li[e], Yanping Xu[g,h,i], Wei Chen[b], Yan Peng[d], Yeqin Hu[b], Lianzhen Lin[d], Xuefei Liu[g,h,i], Shihe Huang[b], Zhijun Zhou[d], Lianghao Zhang[b], Yue Wang[d], Zhi Zhang[b], Kun Deng[d], Zhiwu Xia[b], Qin Gong[d], Wei Zhang[d], Xiaobei Zheng[d], Ying Liu[d], Huichuan Yang[a], Dongbo Zhou[a], Ding Yu[a], Jifeng Hou[n], Zhengli Shi[e], Saijuan Chen[l], Zhu Chen[l,2], Xinxin Zhang[m,2], and Xiaoming Yang[a,b,2]

[a]China National Biotec Group Company Limited, 100029 Beijing, China; [b]National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co. Ltd., 430207 Wuhan, China; [c]First People's Hospital of Jiangxia District, 430200 Wuhan, China; [d]Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, 430207 Wuhan, China; [e]Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071 Wuhan, China; [f]WuHan Jinyintan Hospital, 430023 Wuhan, China; [g]Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China; [h]National Research Center for

s.2004168117, March 2020

FDA Approved a Clinical Trial for Convalescent Plasma Therapy (CPT)

- Patients exhibited strong positive responses within days
-Success of CPT validates neutralizing Abs as effective therapy for COVID19
-Next-generation therapy should be a recombinant neutralizing Ab
-Recombinant Ab will enhance efficacy while obviating limits of CPT
  - -Defined and consistent formulation and activity
  - -Highly stable single agent optimized for neutralization
  - -High purity guarantees high safety compared with undefined plasma



Chest CTs of two patients. **(A)** Chest CT of patient 9 obtained on February 9 (7 dpoi) before CP transfusion (10 dpoi) showed ground-glass opacity with uneven density involving the multilobal segments of both lungs. The heart shadow outline was not clear. The lesion was close to the pleura. **(B)** CT Image of patient 9 taken on February 13 (13 dpoi) showed the absorption of bilateral ground-glass opacity after CP transfusion. (C) Chest CT of patient 10 was obtained on February 8 (19 dpoi) before CP transfusion (20 dpoi). The brightness of both lungs was diffusely decreased, and multiple shadows of high density in both lungs were observed. (D) Chest CT of patient 10 on February 18 (29 dpoi) showed those lesions improved after CP transfusion

Toronto Recombinant Antibody Centre

A High-throughput synthetic antibody platform **applied to COVID-19**

Highly Validated Technology

- a fully human protein
- Highly stable
- Long half-life (weeks)
- Highly potent
- Highly specific
- Low immunogenicity
- Identical to natural neutralizing antibodies
- **A validated human therapeutic**
- **(> 50 approved drugs)**







-Single, highly validated human framework (Hereceptin, Avastin, Xolair, etc.)

-High stability and yield, low immunogenicity

-Minimal targeted synthetic CDR diversity

→Diverse functions with fixed biophysics

→Modular design

Antibodies bind specifically and block ACE2 binding



Antibodies are drug-like

EC_{50} affinity estimation by ELISA



Binding kinetics by BLI

Binding to SARS2 spike



Negative control



SEC profile versus Herceptin standard

Antibodies are Potent Anti-viral Drugs



IgG 15033 Derivatives with Optimized Light Chain

Optimized variants with two substitutions in CDR-L3

Maintain high yield, drug-like SEC, stability

Exhibit ultra-high affinity for spike protein (>100-fold improvement)

IgG ID	K_D (pM)	k_{on} ($10^5 M^{-1}s^{-1}$)	k_{off} ($10^{-5}s^{-1}$)
parental IgG 15033	320 ± 10	9.6 ± 0.1	31 ± 0.8
hk L3 AM1	170 ± 14	8.5 ± 0.2	15 ± 1.2
hk L3 AM2	610 ± 19	12 ± 0.3	72 ± 1.5
hk L3 AM3	420 ± 17	8.5 ± 0.2	36 ± 1.2
hk L3 AM4	330 ± 10	10 ± 0.1	34 ± 0.8
hk L3 AM5	500 ± 10	11 ± 0.1	5 ± 0.8
hk L3 AM6	76 ± 14	8.4 ± 0.2	6.4 ± 1.2
hk L3 AM7	<1	8.6 ± 0.2	<0.1
hk L3 AM8	77 ± 10	10 ± 0.2	7.8 ± 1.0
hk L3 AM9	360 ± 16	12 ± 0.3	42 ± 1.5
hk L3 AM10	100 ± 10	19 ± 0.4	19 ± 1.3
hk L3 AM11	200 ± 10	12 ± 0.2	24 ± 1.0
hk L3 AM12	51 ± 12	13 ± 0.3	6.4 ± 1.5
hk L3 AM13	210 ± 10	14 ± 0.2	30 ± 1.0
hk L3 AM14	130 ± 10	13 ± 0.2	17 ± 1.1
hk L3 AM15	400 ± 11	14 ± 0.2	54 ± 1.2
hk L3 AM16	340 ± 12	13 ± 0.2	44 ± 1.3
hk L3 AM17	250 ± 10	14 ± 0.2	34 ± 1.1

15033 parent (85 mg/L)



15033-AM7 (150 mg/L)





Synthetic antibodies enable modular design: Facile engineering of multivalent drug-like antibodies



Synthetic multivalent antibodies: Enhanced affinity and potency in anti-viral assays



Project Timeline: Anti-COVID19 Antibody Development

Parameter	Method	Numbers	Timeline
Pooled selections	Phage display	$>10^{10}$	3/24 – 3/29
Binding screen	Phage ELISA	384	3/30
Host receptor blocking screen	Phage ELISA	358	3/30
IgG production	Mammalian cell expression	66	3/31 – 4/11
Identification of unique IgGs	DNA sequencing	38	4/8
IgG binding to virus	ELISA	38	4/12
Receptor blocking confirmation	ELISA	~15	4/12
Affinity	Quantitative virus binding	~10 (sub-nanomolar)	4/13
Biophysical characteristics	Yield, solubility, heterogeneity	4 (top leads)	4/13
In vitro virus neutralization	*In vitro* cell assay	4	4/27
In vivo virus neutralization	Human trials	1	Soon

Anti-COVID-19 Antibodies: Beyond the RBD

ViRNA therapeutics

- Selected against purified SARS-CoV-2 RBD
  - Screened 384 clones by ELISA
  - Identified 358 RBD-positive clones
  - 92 sequence-unique, RBD-binding clones

- Selected against VLPs pseudo-typed with SARS-CoV-2 spike
  - Screened 192 clones by ELISA
  - Identified 61 spike-positive clones
  - 24 sequence-unique clones (23 spike-binding, 1 RBD binding)

- Selected against purified SARS-CoV-2 spike protein
  - Screened 192 clones by ELISA
  - Identified 184 spike-positive clones
  - 87 sequence-unique clones

Thousands of potential biologic drugs: Well-suited for testing in advanced cell/tissue models

Lung-on-a-chip: Human Relevant System for Testing COVID-19 Therapeutics



- Extracellular matrix and cell interactions
- Cell shape and cyto-architecture
- Tissue-tissue interactions
- Mechanical forces
- Dynamic flow system
- Resident or circulating immune cells can be included

Angiotensin Converting Enzyme Receptor 2 (ACE-2) Expression





https://doi.org/10.1101/2020.04.13.039917

Nicole Kleinstreuer

Sidhu Lab

Donnelly Centre

Christine Misquitta
Andreas Ernst
Yuyong Tong
Fred Fellouse
Helena Persson
Zvezdan Pavlovic
Andreas Ernst
Wei Zhang
Maryna Gorelik
Gianluca Veggiani
Joan Teyra
Pankaj Garg
Gang Chen
Moshe Ben-David
Bradley Yates
Jaspal Singh
Alia Pavlenco
Linda Beatty
Wei Ye
Nick Jarvik
Jun Gu
Megan McLaughlin
Isabel Leung
Hayoung Yoo
Kristin Kantautas
Natasha Pascoe
Gregory Martyn
Deelaka Wellipilli

TRAC

Shane Miersch
Mart Ustav
Jarret Adams
Isabelle Pot
Levi Blazer
Lia Cardarelli
Haiming Huang
Dewald van Dyk
Xiaowei Wang
Zhijian Li
Lori Dawn Moffat
Jacob Turowec
Sunandan Banerjee
Xunyi Luo
Helen Zhao
Cathy Horvatin
Sherry Lamb-Mariette
Vincent Nadeem
Xin Zhao
Dahlia Kasimer
Lynda Ploder
Galina Khutoreskaya
Ping Huang

Funding

University of Toronto
CIHR
Genome Canada
Ontario Research Fund
OICR
CFI
NIH
Reflexion

Questions



Answers